Search results for "Ovarian Neoplasm"

showing 3 items of 153 documents

Robotic Versus Laparoscopic Staging for Early Ovarian Cancer: A Case-Matched Control Study.

2017

Abstract Study Objective To evaluate the feasibility, surgical outcome, and oncologic results observed after robotic staging compared with conventional laparoscopic staging for patients with early-stage ovarian cancer patients. Design A retrospective cohort study (Canadian Task Force classification II-2). Setting Catholic University of the Sacred Heart, Rome, Italy. Patients Ninety-six patients underwent minimally invasive staging for presumed stage I ovarian cancer; 32 underwent the robotic approach (cases), and 64 underwent the laparoscopic approach (controls). Measurements and Main Results There was no statistically significant difference between the 2 approaches with regard to final Fed…

medicine.medical_specialtymedicine.medical_treatmentOperative TimeHysterectomy03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProceduresmedicineHumansRobotic surgeryStage (cooking)LaparoscopyAgedNeoplasm StagingRetrospective StudiesOvarian Neoplasms030219 obstetrics & reproductive medicineHysterectomymedicine.diagnostic_testbusiness.industryCase-control studyObstetrics and GynecologyRobotic Surgical ProceduresRobotic surgeryRetrospective cohort studyMiddle Agedmedicine.diseaseearly ovarian cancer; laparoscopy; robotic surgerySurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAOutcome and Process Assessment Health CareItaly030220 oncology & carcinogenesisCase-Control StudiesEarly ovarian cancerFemaleLaparoscopyOvarian cancerbusinessJournal of minimally invasive gynecology
researchProduct

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

1999

Two biallelic polymorphisms in introns 3 and 6 of the p53 gene were analysed for a possible risk-modifying effect for ovarian cancer. Germline DNA was genotyped from 310 German Caucasian ovarian cancer patients and 364 healthy controls. We also typed 124 affected and 276 unaffected female carriers with known deleterious BRCA1 or BRCA2 germline mutation from high-risk breast-ovarian cancer families. Genotyping was based on PCR and high-resolution gel electrophoresis. German ovarian cancer patients who carried the rare allele of the MspI restriction fragment length polymorphism (RELP) in intron 6 were found to have an overall 1.93-fold increased risk (95% confidence internal (CI) 1.27–2.91) w…

p53AdultCancer Researchendocrine system diseasesAdolescentGenotypeGenes BRCA1BiologypolymorphismGermline mutationRisk FactorsGenotypemedicineTumor Cells CulturedHumansAlleleAllele frequencyGerm-Line MutationAgedGeneticsAged 80 and overBRCA2 ProteinOvarian NeoplasmsGenetic Carrier ScreeningCancerGenetic VariationRegular ArticleMiddle Agedmedicine.diseaseBRCA2 ProteinBRCA1Genes p53BRCA2IntronsNeoplasm Proteinsovarian cancerOncologyCase-Control StudiesCancer researchFemaleRestriction fragment length polymorphismOvarian cancergenetic susceptibilityTranscription FactorsBritish Journal of Cancer
researchProduct